Document Detail


Quantitative proteomic analysis reveals the perturbation of multiple cellular pathways in jurkat-T cells induced by doxorubicin.
MedLine Citation:
PMID:  20822187     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Doxorubicin remains an important part of chemotherapy regimens in the clinic and is considered an effective agent in the treatment of acute lymphoblastic leukemia (ALL). Although the cellular responses induced by doxorubicin treatment have been investigated for years, the precise mechanisms underlying its cytotoxicity and therapeutic activity remain unclear. Here we utilized mass spectrometry, together with stable isotope labeling by amino acids in cell culture (SILAC), to analyze comparatively the protein expression in Jurkat-T cells before and after treatment with a clinically relevant concentration of doxorubicin. We were able to quantify 1066 proteins in Jurkat-T cells with both forward and reverse SILAC measurements, among which 62 were with significantly altered levels of expression induced by doxorubicin treatment. These included the up-regulation of core histones, heterogeneous nuclear ribonucleoproteins, and superoxide dismutase 2 as well as the down-regulation of hydroxymethylglutaryl-CoA synthase and farnesyl diphosphate synthase. The latter two are essential enzymes for cholesterol biosynthesis. We further demonstrated that the doxorubicin-induced growth inhibition of Jurkat-T cells could be rescued by treatment with cholesterol, supporting that doxorubicin exerts its cytotoxic effect, in part, by suppressing the expression of hydroxymethylglutaryl-CoA synthase and farnesyl diphosphate synthase, thereby inhibiting the endogenous production of cholesterol. The results from the present study provide important new knowledge for gaining insights into the molecular mechanisms of action of doxorubicin.
Authors:
Xiaoli Dong; Lei Xiong; Xinning Jiang; Yinsheng Wang
Related Documents :
19840447 - Mdr reversal activity of bromotetrandrine in vitro and in vivo.
16648557 - A t3587g germ-line mutation of the mdr1 gene encodes a nonfunctional p-glycoprotein.
19918367 - Effect of magnetic nanoparticles of fe3o4 and 5-bromotetrandrine on reversal of multidr...
2565017 - Preparation and utility of a radioiodinated analogue of daunomycin in the study of mult...
24333597 - Lineage specification in the early mouse embryo.
7459717 - Stable isotope fractionation by clostridium pasteurianum. 3. effect of seo32- on the ph...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2010-09-23
Journal Detail:
Title:  Journal of proteome research     Volume:  9     ISSN:  1535-3907     ISO Abbreviation:  J. Proteome Res.     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-11-05     Completed Date:  2011-03-07     Revised Date:  2014-09-12    
Medline Journal Info:
Nlm Unique ID:  101128775     Medline TA:  J Proteome Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  5943-51     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cell Proliferation / drug effects
Cholesterol / biosynthesis,  pharmacology
Doxorubicin / pharmacology*
Gene Expression Regulation / drug effects
Humans
Jurkat Cells
Metabolic Networks and Pathways / drug effects*,  genetics
Proteomics / methods*
T-Lymphocytes / chemistry*
Grant Support
ID/Acronym/Agency:
R01 CA 116522/CA/NCI NIH HHS; R01 CA116522/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
80168379AG/Doxorubicin; 97C5T2UQ7J/Cholesterol
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mass spectrometric immunoassay for quantitative determination of protein biomarker isoforms.
Next Document:  Role of Hmbox1 in endothelial differentiation of bone-marrow stromal cells by a small molecule.